Let’s cover some of the most serious, yet silent, symptoms of ATTR-CM you NEED to know and what you can do to protect ...

Amyloidosis is a condition where a protein ... These abnormally shaped proteins can build up in many places, including nerves or the heart. When the buildup happens in the heart, it causes the ...

When this happens, abnormal proteins (amyloids) build up in the heart ... at risk for cardiac amyloidosis, Arora said. However, research suggests that people with the transthyretin (TTR) mutation ...

which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious ...

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.

Researchers developed trehalose-functionalized peptide amphiphiles (TPAs) that self-assemble into supramolecular ...

Treatment modalities include liver transplantation for transthyretin-related (ATTR ... indispensable in the diagnosis and follow-up of AL amyloidosis. Manipulation of amyloid deposition and ...

its Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). These findings were published in Journal of the American College of Cardiology (JACC) in the Special Focus Issue ...

While receiving treatment for a car accident ten years ago, Mr Chua learnt that he had an abnormal build-up of protein in his ...

BridgeBio Pharma announced promising results from its Phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy ... there was up to a 31.6% reduction in mortality risk over 30 months.

Vutrisiran is currently approved in the European Union (EU) under the brand name AMVUTTRA ® for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage ...